Phase 1 Trial of Oral KORSUVA (CR845/difelikefalin) in Chronic Liver Disease (CLD) Patients
Phase of Trial: Phase I
Latest Information Update: 12 May 2019
Price : $35 *
At a glance
- Drugs Difelikefalin (Primary)
- Indications Pruritus
- Focus Adverse reactions; Pharmacokinetics
- 12 May 2019 Results published in the Cara Therapeutics Media Release
- 06 Nov 2018 According to Cara Therapeutics media release, the Company plans to announce top-line data within the fourth quarter of 2018.
- 06 Nov 2018 Status changed from recruiting to active, no longer recruiting, according to a Cara Therapeutics media release.